78,400 Shares in Cogent Biosciences, Inc. $COGT Acquired by JTC Employer Solutions Trustee Ltd

JTC Employer Solutions Trustee Ltd bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 78,400 shares of the technology company’s stock, valued at approximately $3,019,000. JTC Employer Solutions Trustee Ltd owned about 0.06% of Cogent Biosciences at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of COGT. EverSource Wealth Advisors LLC lifted its position in Cogent Biosciences by 1,164.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares during the last quarter. Osaic Holdings Inc. lifted its position in Cogent Biosciences by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after buying an additional 1,333 shares during the last quarter. Strs Ohio bought a new stake in Cogent Biosciences in the 1st quarter worth approximately $36,000. Global Retirement Partners LLC bought a new stake in Cogent Biosciences in the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. lifted its position in Cogent Biosciences by 414.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after buying an additional 1,032 shares during the last quarter.

Cogent Biosciences Stock Performance

Shares of COGT stock opened at $35.38 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. Cogent Biosciences, Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $43.73. The stock has a 50 day moving average price of $35.27 and a two-hundred day moving average price of $36.72. The company has a market capitalization of $6.05 billion, a P/E ratio of -16.30 and a beta of 0.37.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). Analysts expect that Cogent Biosciences, Inc. will post -2.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on COGT. Wedbush restated an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a research report on Tuesday, March 17th. Piper Sandler boosted their price objective on Cogent Biosciences from $39.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Robert W. Baird set a $35.00 price objective on Cogent Biosciences in a research report on Thursday, February 19th. Wall Street Zen downgraded Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Finally, Jefferies Financial Group began coverage on Cogent Biosciences in a research report on Monday, March 16th. They issued a “buy” rating and a $55.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $43.73.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.